Table of Contents
- What is Allocetra?
- How Does Allocetra Work?
- What Condition Does Allocetra Treat?
- Clinical Trial Details
- Who Can Participate in the Trial?
- What to Expect During the Trial
- Potential Benefits and Risks
What is Allocetra?
Allocetra, also known as Allocetra-OTS, is a new medication being studied for the treatment of knee osteoarthritis[1]. It is a unique type of treatment called a cell therapy, which means it uses living cells as a therapeutic agent. Specifically, Allocetra is made up of allogeneic peripheral blood mononuclear cells induced to an early apoptotic state[1]. Let’s break down what this means:
- Allogeneic: This means the cells come from a donor, not the patient themselves.
- Peripheral blood mononuclear cells: These are important cells in our immune system, including lymphocytes and monocytes.
- Induced to an early apoptotic state: The cells have been treated to enter the early stages of cell death, which can have therapeutic effects.
How Does Allocetra Work?
While the exact mechanism of action is still being studied, Allocetra is designed to be injected directly into the knee joint of patients with osteoarthritis[1]. The apoptotic cells in Allocetra are believed to have anti-inflammatory properties, which could help reduce pain and improve joint function in people with knee osteoarthritis.
What Condition Does Allocetra Treat?
Allocetra is being developed to treat knee osteoarthritis[1]. Osteoarthritis is a common joint condition that occurs when the protective cartilage that cushions the ends of your bones wears down over time. In knee osteoarthritis, this happens in the knee joint, leading to pain, stiffness, and reduced mobility.
Clinical Trial Details
Allocetra is currently being studied in a Phase 1/2a clinical trial[1]. This means it’s in the early stages of testing in humans. The trial has two main parts:
- Safety run-in phase: This phase aims to determine the safety and tolerability of different doses of Allocetra when injected into the knee joint.
- Randomized phase: This phase will compare Allocetra to a placebo (a treatment with no active ingredients) to assess its safety, tolerability, and effectiveness.
Who Can Participate in the Trial?
The trial has specific criteria for who can participate. Some key inclusion criteria are[1]:
- Age 45-80 years
- Chronic knee osteoarthritis with significant pain
- X-ray evidence of knee osteoarthritis
- Failed to respond to at least 3 months of conventional therapy
There are also many exclusion criteria, such as recent knee surgeries, other severe health conditions, or use of certain medications. It’s important to note that these criteria are designed to ensure the safety of participants and the reliability of the study results.
What to Expect During the Trial
If you participate in the trial, you can expect[1]:
- To receive injections of either Allocetra or a placebo directly into your knee joint
- Regular check-ups and assessments of your knee pain and function
- Questionnaires about your pain levels and quality of life
- Monitoring for any side effects or adverse events
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks to participating in this trial[1]:
Potential benefits:
- Reduction in knee pain
- Improved knee function and mobility
- Better quality of life
- Contributing to the development of a new treatment for knee osteoarthritis
Potential risks:
- Side effects from the treatment (which are still being studied)
- Discomfort from the knee injection
- No improvement in symptoms (especially if assigned to the placebo group)
It’s important to discuss these potential benefits and risks with your doctor and the study team before deciding to participate in any clinical trial.
